论文部分内容阅读
目的探讨唑来膦酸与伊班膦酸钠对骨肿瘤患者的疗效影响。方法选取2015年8月至2016年8月间山东单县海吉亚医院收治的104例骨肿瘤患者,采用随机数字表法分为观察组与对照组,每组52例。观察组采用伊班膦酸钠治疗,对照组采用唑来膦酸治疗,比较两组患者的疼痛治疗效果、不良反应和生活质量。结果治疗后观察组患者视觉模拟评分为(4.3±1.5)分,显著低于对照组的(6.0±1.6)分;观察组患者不良反应发生率为9.6%,低于对照组的26.9%;观察组患者Kamofsky评分为(58.5±8.5)分,显著高于对照组的(48.5±7.5)分;观察组患者药物治疗费用为(2025.5±70.5)元,显著低于对照组的(4052.5±80.5)元,以上两组比较,差异均有统计学意义(均P<0.05)。结论相比唑来膦酸,伊班膦酸钠可有效降低骨肿瘤患者的疼痛阈值,提高生活质量,不良反应少,治疗费用低。
Objective To investigate the effect of zoledronic acid and ibandronate on the efficacy of bone tumor patients. Methods A total of 104 patients with bone tumor who were treated in Shanhai Hospital of Shan County, Shandong Province from August 2015 to August 2016 were divided into observation group and control group by random number table, with 52 cases in each group. The observation group was treated with ibandronate, while the control group was treated with zoledronic acid. The pain management, side effects and quality of life were compared between the two groups. Results After the treatment, the visual analog scale in the observation group was (4.3 ± 1.5) points, which was significantly lower than that in the control group (6.0 ± 1.6). The incidence of adverse reactions in the observation group was 9.6%, which was lower than that in the control group (26.9%). The Kamofsky score was (58.5 ± 8.5) points higher than that of the control group (48.5 ± 7.5) points. The cost of medication in the observation group was (2025.5 ± 70.5) yuan, significantly lower than that of the control group (4052.5 ± 80.5) Yuan, the above two groups, the differences were statistically significant (P <0.05). Conclusion Compared with zoledronic acid, ibandronate sodium can effectively reduce the pain threshold of patients with bone tumors, improve quality of life, fewer adverse reactions, and low cost of treatment.